Citius Pharmaceuticals, Inc.
CTXRHealthcare|Biotechnology|US
$0.55
-0.01 (-2.21%)
DCF Value
$0.92
Cash / Share
$0.65
Financials
Financial Snapshot
Market Cap
$15.0M
Enterprise Value
$5.1M
Revenue (TTM)
$7.1M
Net Income (TTM)
-$46.3M
Cash & Investments
$17.0M
Net Cash
$9.8M
Free Cash Flow (TTM)
-$34.9M
Operating CF (TTM)
-$34.9M
Debt/Equity
0.11
Cash Runway & Burn Rate
Cash on Hand
$17.0M
Quarterly Burn
$8.7M
Monthly Burn
$2.9M
Est. Runway
~2.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $294.4K | $3.2M | $9.2M | $7.9M | $13.9M | $70.1M | $41.7M | $26.5M | $3.3M | $4.3M | $17.0M | |
| Operating Cash Flow | -$5.9M | -$8.0M | -$11.3M | -$12.4M | -$16.9M | -$24.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M | -$34.9M | |
| Free Cash Flow | -$5.9M | -$8.0M | -$11.3M | -$12.4M | -$16.9M | -$64.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M | -$34.9M | |
| Capital Expenditure | $0.00 | -$2.1K | $0.00 | $0.00 | -$1.8K | -$40.0M | $0.00 | $0.00 | $0.00 | $0.00 | $4.00 | |
| Financing Cash Flow | $5.3M | $10.9M | $17.3M | $11.1M | $22.9M | $120.5M | $0.00 | $13.8M | $10.0M | $33.3M | $58.5M |
R&D Spending
R&D (TTM)
$5.9M
R&D Intensity
83.4%
R&D Growth vs Prior
-35.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.1M | |
| R&D Expense | $2.9M | $2.9M | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | $9.2M | $5.9M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | — | 83.4% | |
| SG&A | $4.5M | $7.1M | $7.2M | $7.0M | $8.7M | $11.1M | $15.7M | $21.9M | $18.2M | $18.5M | $43.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.1M | |
| Cost of Revenue | $1.3K | $2.6K | $1.8K | $893.00 | $152.4K | $164.9K | $0.00 | $0.00 | $209.6K | $214.3K | $5.7M | |
| Gross Profit | -$1.3K | -$2.6K | -$1.8K | -$893.00 | -$152.4K | -$164.9K | $0.00 | $0.00 | -$209.6K | -$214.3K | $1.4M | |
| R&D | $2.9M | $2.9M | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | $9.2M | $5.9M | |
| SG&A | $4.5M | $7.1M | $7.2M | $7.0M | $8.7M | $11.1M | $15.7M | $21.9M | $18.2M | $18.5M | $43.3M | |
| Operating Income | -$7.4M | -$10.0M | -$13.8M | -$15.6M | -$17.7M | -$23.5M | -$33.3M | -$36.7M | -$42.0M | -$38.5M | -$61.4M | |
| Interest Expense | $9.0K | $850.8K | $15.8K | $16.4K | $15.7K | $10.8K | $0.00 | $0.00 | $0.00 | $267.8K | $695.3K | |
| Pretax Income | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.1M | -$32.0M | -$38.8M | -$38.7M | -$58.0M | |
| Net Income | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.1M | -$37.4M | -$46.3M | |
| EPS (Diluted) | -2.29 | -1.89 | -1.17 | -0.77 | -11.20 | -5.64 | -5.75 | -5.57 | -5.97 | -3.38 | -2.11 | |
| EBITDA | -$7.4M | -$10.0M | -$13.8M | -$15.5M | -$17.6M | -$23.4M | -$33.1M | -$36.5M | -$38.6M | -$38.2M | -$57.2M | |
| Shares Out. (M) | 0.24 | 0.37 | 0.72 | 1.34 | 1.57 | 4.34 | 5.84 | 6.05 | 11.59 | 11.07 | 26.17 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $294.4K | $3.2M | $9.2M | $7.9M | $13.9M | $70.1M | $41.7M | $26.5M | $3.3M | $4.3M | $17.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $892.8K | $3.4M | $10.1M | $7.9M | $14.0M | $72.8M | $44.6M | $34.4M | $14.2M | $27.9M | $43.3M | |
| Total Assets | $22.0M | $24.4M | $31.1M | $29.0M | $43.8M | $142.4M | $114.0M | $103.6M | $116.7M | $130.9M | $142.3M | |
| Total Current Liabilities | $5.2M | $2.5M | $3.2M | $4.6M | $4.1M | $4.0M | $4.5M | $5.8M | $35.8M | $44.9M | $51.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $164.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.0M | |
| Total Liabilities | $5.2M | $2.5M | $3.2M | $4.6M | $10.1M | $9.6M | $10.6M | $12.2M | $42.5M | $53.4M | $66.3M | |
| Stockholders' Equity | $16.8M | $21.9M | $27.9M | $24.4M | $33.7M | $132.2M | $102.8M | $90.8M | $70.1M | $67.6M | $66.6M | |
| Retained Earnings | -$17.3M | -$27.7M | -$40.3M | -$55.8M | -$70.6M | -$96.0M | -$129.7M | -$162.2M | -$201.4M | -$238.8M | -$277.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.9M | -$8.0M | -$11.3M | -$12.4M | -$16.9M | -$24.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M | -$34.9M | |
| Capital Expenditure | $0.00 | -$2.1K | $0.00 | $0.00 | -$1.8K | -$40.0M | $0.00 | $0.00 | $0.00 | $0.00 | $4.00 | |
| Free Cash Flow | -$5.9M | -$8.0M | -$11.3M | -$12.4M | -$16.9M | -$64.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M | -$34.9M | |
| Investing Cash Flow | $255.7K | -$2.1K | $0.00 | $0.00 | -$1.8K | -$40.0M | $0.00 | $0.00 | -$5.0M | -$5.8M | -$12.8M | |
| Financing Cash Flow | $5.3M | $10.9M | $17.3M | $11.1M | $22.9M | $120.5M | $0.00 | $13.8M | $10.0M | $33.3M | $58.5M | |
| Issuance of Stock | $5.4M | $6.7M | $16.2M | $11.1M | $15.6M | $89.4M | $0.00 | $13.8M | $13.8M | $32.3M | $49.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$100.0K | $4.2M | $0.00 | $0.00 | $164.6K | -$173.0K | $0.00 | $0.00 | $0.00 | $1.0M | $7.6M | |
| Stock Based Comp. | $732.2K | $986.6K | $779.7K | $716.0K | $803.3K | $1.5M | $3.9M | $6.6M | $11.8M | $10.8M | $11.0M | |
| Net Change in Cash | -$381.8K | $2.9M | $6.0M | -$1.3M | $6.0M | $56.2M | -$28.4M | -$15.2M | -$23.2M | $1.0M | $10.9M |
Dilution Tracker
Shares outstanding grew 606.3% over 5 years — significant dilution
Shares Outstanding
27M
5-Year Share Growth
+606.3%
Stock Issuance (TTM)
$49.9M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.24 | 0.37 | 0.72 | 1.34 | 1.57 | 4.34 | 5.84 | 6.05 | 11.59 | 11.07 | 26.17 | |
| Change vs Prior % | — | 51.3% | 95.7% | 87.9% | 16.6% | 177.3% | 34.5% | 3.6% | 91.5% | -4.5% | 136.5% | |
| Stock Issuance | $5.4M | $6.7M | $16.2M | $11.1M | $15.6M | $89.4M | $0.00 | $13.8M | $13.8M | $32.3M | $49.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $732.2K | $986.6K | $779.7K | $716.0K | $803.3K | $1.5M | $3.9M | $6.6M | $11.8M | $10.8M | $11.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | 20.0% | |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | -863.9% | |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | -651.3% | |
| EBITDA Margin % | — | — | — | — | — | — | — | — | — | — | -804.9% | |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | -490.7% | |
| ROE % | -49.5% | -47.3% | -45.0% | -63.9% | -52.1% | -17.4% | -32.7% | -35.8% | -55.9% | -55.4% | -67.1% | |
| ROA % | -37.8% | -42.5% | -40.4% | -53.7% | -40.1% | -16.2% | -29.5% | -31.4% | -33.6% | -28.6% | -32.5% | |
| ROIC % | -42.7% | -45.1% | -49.2% | -63.5% | -44.3% | -17.0% | -30.4% | -37.5% | -51.8% | -44.2% | -67.6% | |
| R&D / Revenue % | — | — | — | — | — | — | — | — | — | — | 83.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -96.0% | 33.4% | 49.1% | -16962.0% | -8.2% | 100.0% | 0.0% | 0.0% | -2.2% | |
| Operating Income | -130.6% | -34.1% | -38.1% | -13.1% | -13.5% | -32.9% | -41.6% | -10.3% | -14.3% | 8.3% | |
| Net Income | -185.8% | -25.2% | -20.7% | -24.3% | -12.6% | -31.4% | -45.9% | 3.3% | -20.3% | 4.4% | |
| EPS (Diluted) | -67.2% | 17.5% | 38.1% | 34.2% | -1354.5% | 49.6% | -2.0% | 3.1% | -7.2% | 43.4% | |
| Operating Cash Flow | -147.4% | -35.1% | -42.0% | -9.9% | -36.1% | -43.2% | -17.0% | -2.5% | 3.0% | 5.8% | |
| Free Cash Flow | -147.4% | -35.1% | -41.9% | -9.9% | -36.1% | -279.5% | 55.9% | -2.5% | 3.0% | 5.8% | |
| R&D Expense | 63.2% | 0.1% | 123.5% | 31.0% | 2.5% | 38.9% | 44.2% | -16.1% | -19.7% | -23.1% | |
| SG&A Expense | 215.2% | 56.1% | 2.5% | -3.1% | 24.9% | 27.2% | 40.7% | 39.9% | -16.7% | 1.6% | |
| Total Assets | 2860.1% | 11.2% | 27.2% | -6.6% | 51.0% | 225.4% | -20.0% | -9.1% | 12.6% | 12.2% | |
| Book Value / Share | 1646.1% | -13.5% | -35.1% | -53.4% | 18.5% | 42.2% | -42.1% | -14.6% | -57.7% | 9.6% | |
| Debt | 0.0% | -74.3% | 0.0% | 0.0% | 681.7% | -36.7% | -20.7% | -29.0% | -45.4% | 589.8% | |
| Diluted Shares | 70.7% | 51.3% | 95.7% | 87.9% | 16.6% | 177.3% | 34.5% | 3.6% | 91.5% | -4.5% |
Valuation
P/E (TTM)At Loss
P/S2.11
P/B0.21
10Y Low / Med / High0.20 / 1.31 / 3.40
EV/EBITDAAt Loss
EV/Revenue0.72
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.92
Cash / Share
$0.65
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -103.11 | -41.70 | -35.68 | -24.60 | -2.32 | -9.00 | -5.26 | -3.07 | -2.10 | -0.37 | -0.26 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.11 | |
| P/B Ratio | 3.40 | 1.31 | 1.07 | 1.04 | 1.21 | 1.67 | 1.72 | 1.14 | 2.07 | 0.20 | 0.21 | |
| EV/EBITDA | -7.71 | -2.58 | -1.51 | -1.14 | -1.61 | -6.47 | -4.10 | -2.12 | -3.68 | -0.30 | -0.09 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.72 |
Analyst Estimates & Quality
Altman Z-Score
-4.03
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $20.5M | $50.7M | $74.6M |
| Net Income | -$15.9M | -$7.4M | -$1.1M |
| EPS | $-1.44 | $-0.67 | $-0.10 |
| # Analysts (EPS) | 1 | 1 | 1 |